<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02765100</url>
  </required_header>
  <id_info>
    <org_study_id>1406015184</org_study_id>
    <nct_id>NCT02765100</nct_id>
  </id_info>
  <brief_title>Depression, Obesity and Inflammatory Markers</brief_title>
  <official_title>Depression, Obesity and Inflammatory Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weill Cornell Medical College in Qatar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand the relationship between bipolar disorder,
      body weight, and inflammation in the body (N=180). People with bipolar depression (N =
      50)will be offered a place in a pilot study looking to see if the antibiotic minocycline
      added to current psychiatric medications has an effect on mood. A separate consent form will
      be provided for the pilot study. Numerous studies have documented the presence of altered
      immune function and elevation of inflammatory markers in patients with depression. Studies
      suggest that major depression is accompanied by immune dysregulation and activation of the
      inflammatory response system. While a small number of studies have found elevated
      inflammatory markers in bipolar mania, very little has been reported about inflammation in
      bipolar depression, and none of these studies have addressed the relationship of inflammatory
      markers with obesity in bipolar disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1 (N=180)will examine relationships between the levels of the inflammatory markers and
      current clinical state (depressed, manic or euthymic) with the hypothesis that Inflammatory
      markers will be higher in depression and mania relative to the euthymic state.

      Aim 2 (N=180)will examine relationships between inflammatory markers and BMI in bipolar
      patients with the hypothesis that inflammatory markers will correlate positively with BMI.

      Aim 3 (N=180)will examine the relationship between depression, obesity and inflammatory
      markers with the hypothesis that depressed (or manic) bipolar patients who are also obese
      will have higher inflammatory markers than either obese euthymic patients or non-obese
      depressed or manic patients.

      Aim 4. (N=50) The pilot study will be to conduct a proof of concept add-on treatment study of
      the antibiotic minocycline for bipolar patients who are depressed, likely to be obese and
      likely to have elevated inflammatory markers and increased risk of heart disease. This is a
      proposal to conduct a 2-site trial of 50 subjects to examine the value of minocycline
      augmentation in bipolar depressed patients who are incompletely responsive to initial
      treatment with anti depressants and/or mood stabilizers. The investigators will compare two
      subgroups of depressed patients, those who have high (N=25) versus those who have low (N=25)
      levels of C-reactive protein (CRP).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">October 2019</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Depression as Measured by the Hamilton Depression Scale Collected at Baseline and Week 8</measure>
    <time_frame>Baseline; week 8</time_frame>
    <description>Scale ranges from 0-52. Greater change means greater improvement of depression from baseline to week 8.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Depression</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Low CRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects have CRP &gt; 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High CRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects have CRP =/&gt; 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>Minocycline 100 mg twice a day</description>
    <arm_group_label>High CRP</arm_group_label>
    <arm_group_label>Low CRP</arm_group_label>
    <other_name>Minocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Bipolar Disorder and current depressive symptoms

          -  Hamilton Depression Scale score &gt; 18

          -  Failed an adequate trial of at least one antidepressant or mood stabilizer of at least
             4 weeks duration. Medication history will be recorded using the Antidepressant
             Treatment History Form

          -  18 years or older

          -  Fluent in English or Arabic

          -  Have the capacity to understand the nature of the study and sign the written informed
             consent.

        Exclusion Criteria:

          -  A current diagnosis of Schizophrenia or other psychotic disorder, or Dementia
             Alzheimer Type or related cognitive disorders.

          -  Principal diagnosis of Post-Traumatic Stress Disorder, Anorexia or Bulimia Nervosa,
             Obsessive-Compulsive Disorder. We define principal as the most pressing clinical
             problem.

          -  Pregnant or nursing

          -  Axis II diagnosis of antisocial, schizotypal or severe borderline personality disorder
             (defined as patients who are high risk for being unable to complete the study due to
             hospitalization, suicide attempts, significant self-mutilation, or other
             self-injurious or destructive behavior).

          -  Patients who currently meet criteria for Alcohol or other Substance-Related Dependence
             Disorder (with the exception of nicotine dependence) who require detoxification.

          -  Patients who are unable to read and write English or Arabic.

          -  Patients having serious, unstable or terminal medical or neurologic illness that would
             compromise study participation (i.e., metastatic or advanced malignancy, chronic renal
             failure requiring dialysis, recent myocardial infarction or unstable angina, or &quot;end
             stage&quot; chronic obstructive pulmonary disease). People with common conditions such as
             hypertension, insulin dependent diabetes mellitus, asthma, compensated congestive
             heart failure, a malignancy in remission, treated hypothyroidism, or epilepsy will not
             be excluded from participation.

          -  Autoimmune disease or chronic inflammatory diseases such as psoriasis or Crohn's
             disease

          -  Chronic infection such as hepatitis B or C or HIV

          -  Elevated antinuclear antibody or rheumatoid factor

          -  Oral glucocorticoids in the past 6 months

          -  Methotrexate or NSAID use in the past two weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James H Kocsis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill CMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>May 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <results_first_submitted>June 1, 2020</results_first_submitted>
  <results_first_submitted_qc>June 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2020</results_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Obesity</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data will not be shared.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT02765100/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low CRP</title>
          <description>patients with a baseline C-ReactiveProtein value =/&lt; 3 treated with minocycline 200 mg/d</description>
        </group>
        <group group_id="P2">
          <title>High CRP</title>
          <description>patients with a baseline C-ReactiveProtein value &gt;3 treated with minocycline 200 mg/d</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>subject found ineligible after baseline</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low CRP</title>
          <description>CRP =/&lt; 3</description>
        </group>
        <group group_id="B2">
          <title>High CRP</title>
          <description>CRP &gt; 3</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="7.5"/>
                    <measurement group_id="B2" value="44.5" spread="14.0"/>
                    <measurement group_id="B3" value="48.3" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Qatar</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Depression Scale (HAMD)</title>
          <description>Scores range from 0 (no depression) to 52 (most severe depression)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.8" spread="6.5"/>
                    <measurement group_id="B2" value="23.0" spread="4.1"/>
                    <measurement group_id="B3" value="23.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Depression as Measured by the Hamilton Depression Scale Collected at Baseline and Week 8</title>
        <description>Scale ranges from 0-52. Greater change means greater improvement of depression from baseline to week 8.</description>
        <time_frame>Baseline; week 8</time_frame>
        <population>Three participants not analyzed due to withdrawal from study</population>
        <group_list>
          <group group_id="O1">
            <title>Low CRP</title>
            <description>patients with baseline CRP =/&lt; 3</description>
          </group>
          <group group_id="O2">
            <title>High CRP</title>
            <description>patients with baseline CRP &gt; 3</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Depression as Measured by the Hamilton Depression Scale Collected at Baseline and Week 8</title>
          <description>Scale ranges from 0-52. Greater change means greater improvement of depression from baseline to week 8.</description>
          <population>Three participants not analyzed due to withdrawal from study</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="3.4"/>
                    <measurement group_id="O2" value="-12.0" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is a pilot proof of concept study and does not require formal sample size calculations. High and low CRP groups will be compared on demographic, clinical and biological variables using two-sample t-tests or analysis of variance (ANOVA) tests for continuous variables (for nonparametric continuous variables, either Mann-Whitney tests or Kruskal-Wallis tests will be used) and chi-square tests or Fisher's exact tests for categorical variables.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Unless specified otherwise, each of the statistical tests above will use a two-tailed alpha-level of 0.05.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.4</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <desc>Three participants not evaluated due to early withdrawal from the study</desc>
      <group_list>
        <group group_id="E1">
          <title>Low CRP</title>
          <description>CRP =/&lt; 3</description>
        </group>
        <group group_id="E2">
          <title>High CRP</title>
          <description>CRP &gt; 3</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James H Kocsis, M.D.</name_or_title>
      <organization>Weill Cornell Medicine</organization>
      <phone>212-746-5913</phone>
      <email>jhk2002@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

